Lead Plaintiff Deadline: November 16, 2020
See If You Qualify For Monetary Reward
Please Upload related files below
Fill in below.
Looking for more?
(i) the Company’s orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel’s commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
In order to be included in the lawsuit, you must have incurred a loss on shares of Odonate purchased or acquired during the class period listed above.
If you suffered a loss in Odonate during the relevant time frame, you have until November 16, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.